人附睾蛋白4在卵巢癌中的研究进展-肿瘤学专业毕业论文.pdfVIP

人附睾蛋白4 在卵巢癌中的研究进展 中文摘要 卵巢癌(ovarian cancer)是女性生殖系统最常见的恶性肿瘤，其发病率仅次 于宫颈癌及宫体癌，但其死亡率却居于首位。卵巢癌患者早期常无明显的临床症 状，当大多数患者因出现临床症状而就诊时就已经处于疾病的晚期阶段，预后不 良。而且目前主要筛查方法如阴道超声和血清CA125 等检查均有一定的局限性， 因此亟待寻找更可靠的早期诊断卵巢癌的肿瘤标志物。近几年来人附睾蛋白 4(human epididymis protein 4,HE4）作为一种新型的卵巢癌标志物而被广泛研 究，目前国内外大量研究发现：HE4 不仅可用于卵巢癌的早期诊断和筛查，而且其 水平与卵巢癌的各项临床病理因素、疗效评价、预后及复发之间均有相关性。本 文就血清 HE4 在卵巢癌中的研究进展进行综述，希望对卵巢癌的临床工作有更多 的帮助。 关键词：卵巢癌；人附睾蛋白4 1 Progress of human epididymis protein 4 in ovarian carcinoma English Abstract Ovarian cancer is the most common malignant tumors of female reproductive system, its incidence after cervical cancer and endometrial cancer, but the mortality rate is in the first place. Early ovarian cancer patients often have no obvious clinical symptoms, when most of the patients attend doctors office with clinical symptoms always has been in the late stage of disease, poor prognosis. At present, the main screening methods such as vaginal ultrasound and serum CA125 inspection all have certain limitations, so people need to look for more reliable tumor markers for early diagnosis of ovarian cancer. In recent years, human epididymis protein 4 (HE4) as a new marker of ovarian cancer has been studied widely at home and abroad, a lot of research has found that: HE4 can not only be used in early diagnosis and screening for ovarian cancer, but also its level has the correlation with the various clinical pathologic factors of ovarian cancer, curative effect evaluation, prognosis and recurrence.This article summarized research progress on serum HE4 in ovarian cancer, hoping can give the clinical work of ovarian cance